Clinical Trial

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

Study acronym: GMMG-DADA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-12-03; most recent amendment 2026-03-03.
Status change: Recruiting → Active, Not Recruiting 2026-03-03
Status change: Not Yet Recruiting → Recruiting 2021-08-17
Trial Details
NCT Number NCT04656951
Lead Sponsor University of Cologne
Collaborators: Janssen-Cilag G.m.b.H
Conditions Multiple Myeloma
Enrollment 67 participants
Start Date 2021-06-01
Primary Completion 2025-03-15 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-05